Authorized purpose: Post-processes 3D X-ray angiography to help physicians visualize vasculature during embolization planning.
Clinical role
Post-processing software for the planning phase of embolization that segments vasculature on 3D X-ray angiography and selectively displays vessels from a user-determined point, as an adjunct for physicians; it is not used during therapy delivery.
Images and patients
CBCT · Vasculature throughout the body
Key limitation
Keep in mind: For planning only; injection points require independent confirmation before therapy, and the AI segmentation option was validated for adults only.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Post-processes 3D X-ray angiography to help physicians visualize vasculature during embolization planning.
Which images or clinical context are in scope?Modality: CBCT Anatomy or clinical context: Vasculature throughout the body Input: Contrast-injected 3D X-ray angiography or CBCT acquired during embolization planning.
Who uses it?Intended users: Physicians.
What does the software produce?Output: Segmented vasculature, selective proximal/distal vessel display, and user-defined data export for guidance.
What is its most important limitation?Key limitation: For planning only; injection points require independent confirmation before therapy, and the AI segmentation option was validated for adults only.
Clinical takeaway. Clinical role: Post-processes 3D X-ray angiography to help physicians visualize vasculature during embolization planning.
Evidence takeaway. Evidence from the reviewed source record: FDA reported 207 unique-patient contrast-injected CBCT scans, with vessel-extraction success of 93.7% and root-definition success of 95.2%; diagnostic sensitivity and specificity were not reported.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Post-processes 3D X-ray angiography to help physicians visualize vasculature during embolization planning.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Post-processing software for the planning phase of embolization that segments vasculature on 3D X-ray angiography and selectively displays vessels from a user-determined point, as an adjunct for physicians; it is not used during therapy delivery.
Exact FDA submission
Checked 2026-11-14
Packet wording: "FlightPlan for Embolization is a post processing software package that helps the analysis of 3D X-ray angiography images. Its output is intended to be used by physicians as an adjunct means to help visualize vasculature during the planning phase of embolization procedures." … "The output includes segmented vasculature, and selective display of proximal vessel and distal vessels from a reference point determined by the user.". Read from the exact FDA decision document on 2026-11-14.
FDA reported 207 unique-patient contrast-injected CBCT scans, with vessel-extraction success of 93.7% and root-definition success of 95.2%; diagnostic sensitivity and specificity were not reported.
Exact FDA submission
Checked 2026-09-15
Algorithm success rates are not diagnostic performance metrics.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA reported 207 unique-patient contrast-injected CBCT scans, with vessel-extraction success of 93.7% and root-definition success of 95.2%; diagnostic sensitivity and specificity were not reported.
FDA source
Exact FDA submission
Checked 2026-09-15
Algorithm success rates are not diagnostic performance metrics.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Embo ASSIST AI regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionvxtl_17.0-4.24
IndependenceIndependence not established
K223490
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223490. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Contrast-injected 3D X-ray angiography or CBCT acquired during embolization planning.
Scope: Exact FDA submission. Exact FDA input scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes processing 3D X-ray angiography (CBCT) images acquired from GE HealthCare's interventional X-ray system, saving results with optional export to other applications such as GEHC's Vision Applications for 3D road-mapping, and compliance with the NEMA PS 3.1-3.20 DICOM standard. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "The software process 3D X-ray angiography images (CBCT) acquired from GE HealthCare's interventional X-ray system [K181403]" … "Save results and optionally export them to other applications such as GEHC’s Vision Applications [K092639] for 3D road-mapping.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes software that operates on GE HealthCare's Advantage Workstation (AW) and AW Server platforms as an extension to the Volume Viewer application, and was verified on AW VolumeShare workstation and AW Server platforms. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "operates on GEHC’s Advantage Workstation (AW) [K110834] platform and AW Server (AWS) [K081985] platform, and is an extension to the GE HealthCare’s Volume Viewer application" … "The proposed FlightPlan for Embolization has been successfully verified on the AW VolumeShare workstation [K110834] and AW Server [K081985] platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Segmented vasculature, selective proximal/distal vessel display, and user-defined data export for guidance.
Scope: Exact FDA submission. FDA device-description scope.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes software that operates on GE HealthCare's Advantage Workstation (AW) and AW Server platforms as an extension to the Volume Viewer application, and was verified on AW VolumeShare workstation and AW Server platforms. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "operates on GEHC’s Advantage Workstation (AW) [K110834] platform and AW Server (AWS) [K081985] platform, and is an extension to the GE HealthCare’s Volume Viewer application" … "The proposed FlightPlan for Embolization has been successfully verified on the AW VolumeShare workstation [K110834] and AW Server [K081985] platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes processing 3D X-ray angiography (CBCT) images acquired from GE HealthCare's interventional X-ray system, saving results with optional export to other applications such as GEHC's Vision Applications for 3D road-mapping, and compliance with the NEMA PS 3.1-3.20 DICOM standard. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The software process 3D X-ray angiography images (CBCT) acquired from GE HealthCare's interventional X-ray system [K181403]" … "Save results and optionally export them to other applications such as GEHC’s Vision Applications [K092639] for 3D road-mapping.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
ACR AI Central provides an exact-submission model card for FlightPlan for Embolization; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K223490 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Displays and supports interpretation of digital/digitized dental media, including CBCT and other 2D/3D X-ray images; its Panoramic Curve Proposal generates a proposed dental-arch curve for patients aged 12 years and older with permanent dentition that a clinician can review and adjust.
Authorized purpose: Second Opinion 3D processes dental CBCT radiographs to identify and mark dentition, maxilla, mandible, inferior alveolar canal and mental foramen, maxillary sinus, nasal space, and airway for review by dental health professionals age 12 and older; it is a concurrent or second reader, not a sole diagnosis.
Authorized purpose: Relu Creator manages, transfers, displays, enhances, and analyzes dental and craniomaxillofacial image information and provides design input for dental solutions within the labeled workflow.
Authorized purpose: DS Core CBCT Anatomy uses CBCT and digital-impression data to provide tooth and jaw segmentation, inferior-alveolar-nerve-canal segmentation, panoramic-curve support, and registration for dental professionals.
Modality
CBCT
Anatomy
Teeth; jaws; and the inferior alveolar nerve canal
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.